EPPC Scholar Submits Public Comment Objecting to Novavax Vaccine EUA


Published June 6, 2022

On June 6, 2022, EPPC Fellow David Gortler submitted a public comment to the Food and Drug Administration on a public advisory committee meeting of the Vaccines and Related Biological Products Advisory Committee to discuss an Emergency Use Authorization (EUA) request by Novavax for a vaccine to prevent COVID-19 in individuals 18 years of age and older.

In the comment, Dr. Gortler explains that “the Novavax vaccine should not be granted an EUA because there is no emergency necessitating the emergency approval process and the vaccine trials show evidence of serious risk of heart inflammation.”

Click here to view a PDF of the comment.


Most Read

EPPC BRIEFLY
This field is for validation purposes and should be left unchanged.

Sign up to receive EPPC's biweekly e-newsletter of selected publications, news, and events.

Upcoming Event |

Abraham Lincoln: Redeemer President with Allen Guelzo at Ford’s Theatre

SEARCH

Your support impacts the debate on critical issues of public policy.

Donate today

More in HHS Accountability Project